ciclesonide Side Effects
Also known as: Alvesco
Analysis of 13,075 adverse event reports submitted to the FDA from 2006 to 2025.
Total Reports
13,075
Death-Related
576
4.4% of reports
Hospitalizations
5,864
44.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 576 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 334 |
| ASTHMA | 144 |
| DYSPNOEA | 140 |
| WHEEZING | 97 |
| PNEUMONIA | 86 |
| PRODUCTIVE COUGH | 73 |
| FORCED EXPIRATORY VOLUME DECREASED | 72 |
| OBSTRUCTIVE AIRWAYS DISORDER | 72 |
| ANXIETY | 71 |
| CONDITION AGGRAVATED | 66 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 64 |
| LUNG DISORDER | 64 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 64 |
| THROMBOSIS | 64 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 62 |
| ARTERIOSCLEROSIS | 61 |
| HAEMOPTYSIS | 61 |
| PAIN IN EXTREMITY | 61 |
| HYPOXIA | 60 |
| HYPOTHYROIDISM | 59 |
Reactions in Hospitalization Reports
Top reactions in 5,864 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ASTHMA | 3,280 |
| DYSPNOEA | 2,636 |
| WHEEZING | 2,226 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 1,446 |
| COUGH | 1,189 |
| PNEUMONIA | 1,156 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 1,103 |
| OBSTRUCTIVE AIRWAYS DISORDER | 1,033 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 974 |
| PRODUCTIVE COUGH | 966 |
| CONDITION AGGRAVATED | 693 |
| CHEST DISCOMFORT | 649 |
| MALAISE | 646 |
| FULL BLOOD COUNT ABNORMAL | 642 |
| FATIGUE | 636 |
| DRUG INEFFECTIVE | 624 |
| NASOPHARYNGITIS | 498 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 455 |
| BLOOD PRESSURE INCREASED | 446 |
| HEADACHE | 445 |
Nearby — Related Medications
What the FAERS Data Reveals About ciclesonide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 13,075 voluntary reports linked to ciclesonide and its brand equivalents (Alvesco), spanning 2006 through 2025. Of those, 576 (4.4%) listed death as an outcome and 5,864 (44.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 65% were female and 35% male; age distribution skews toward 45-64, with 3,431 reports in that bracket. The single most reported reaction is asthma with 5,711 submissions, followed by dyspnoea and wheezing.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.